Clinical significance of surgical resection for hepatocellular carcinoma with portal vein invasion: a nationwide cohort study.

IF 6.1 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Hepatobiliary surgery and nutrition Pub Date : 2024-10-01 Epub Date: 2024-06-25 DOI:10.21037/hbsn-23-578
Hye-Sung Jo, Pyoung-Jae Park, Young-Dong Yu, Yoo Jin Choi, Se Hyeon Yu, Dong-Sik Kim
{"title":"Clinical significance of surgical resection for hepatocellular carcinoma with portal vein invasion: a nationwide cohort study.","authors":"Hye-Sung Jo, Pyoung-Jae Park, Young-Dong Yu, Yoo Jin Choi, Se Hyeon Yu, Dong-Sik Kim","doi":"10.21037/hbsn-23-578","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) with portal vein invasion (PVI) is considered an advanced stage with a poor prognosis. Although current guidelines recommend systemic treatment for HCC with PVI, surgical resection could produce acceptable outcomes in selected patients. This study aimed to identify the clinical significance of surgical resection for HCC with PVI patients using a large-scale nationwide registry.</p><p><strong>Methods: </strong>This retrospective, multicenter, observational cohort analyzed data from the Korean Primary Liver Cancer Registry. A total of 16,781 patients who were newly diagnosed with HCC between 2008 and 2018 were enrolled in this study. Patients with worse Child-Turcotte-Pugh scores (≥7) or performance status (≥2) were excluded. Among them, 998 patients who received treatment for HCC with PVI were included in the analysis and were divided into two groups: resection group of 151 (15.1%) and palliative group of 847 (84.9%) who received transarterial and systemic therapy according to the treatment intent. After matching the number and size of the tumors and model for end-stage liver disease (MELD) score between the groups, the final study cohort for analysis comprised 151 (26.6%) patients in the resection group and 417 (73.4%) in the palliative group. The primary endpoints were overall survival (OS) and cancer-specific survival (CSS).</p><p><strong>Results: </strong>The number and maximum size of HCC did not differ between the resection and palliative groups after matching [1 (range, 1-5) <i>vs.</i> 1 (range, 1-6), P=0.11 and 5.5 (range, 1.2-20.6) <i>vs.</i> 6.0 (range, 1.0-20.5) cm, P=0.24, respectively]. Tumor markers, including alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II), also did not differ between the groups (P=0.29 and P=0.36, respectively). The 5-year OS and CSS rates of the resection and palliative groups were 44.8% and 17.4% (P<0.001) and 47.7% and 18.6% (P<0.001), respectively. Multivariate analysis showed that palliative treatment intent was the most significant risk factor for OS and CSS [odds ratio (OR) =2.24; 95% confidence interval (CI): 1.66-3.02; P<0.001 and OR =2.29; 95% CI: 1.68-3.12; P<0.001, respectively].</p><p><strong>Conclusions: </strong>Surgical resection could significantly improve OS and CSS in selected HCC with PVI patients who have preserved liver function and performance status.</p>","PeriodicalId":12878,"journal":{"name":"Hepatobiliary surgery and nutrition","volume":"13 5","pages":"814-823"},"PeriodicalIF":6.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534781/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatobiliary surgery and nutrition","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/hbsn-23-578","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hepatocellular carcinoma (HCC) with portal vein invasion (PVI) is considered an advanced stage with a poor prognosis. Although current guidelines recommend systemic treatment for HCC with PVI, surgical resection could produce acceptable outcomes in selected patients. This study aimed to identify the clinical significance of surgical resection for HCC with PVI patients using a large-scale nationwide registry.

Methods: This retrospective, multicenter, observational cohort analyzed data from the Korean Primary Liver Cancer Registry. A total of 16,781 patients who were newly diagnosed with HCC between 2008 and 2018 were enrolled in this study. Patients with worse Child-Turcotte-Pugh scores (≥7) or performance status (≥2) were excluded. Among them, 998 patients who received treatment for HCC with PVI were included in the analysis and were divided into two groups: resection group of 151 (15.1%) and palliative group of 847 (84.9%) who received transarterial and systemic therapy according to the treatment intent. After matching the number and size of the tumors and model for end-stage liver disease (MELD) score between the groups, the final study cohort for analysis comprised 151 (26.6%) patients in the resection group and 417 (73.4%) in the palliative group. The primary endpoints were overall survival (OS) and cancer-specific survival (CSS).

Results: The number and maximum size of HCC did not differ between the resection and palliative groups after matching [1 (range, 1-5) vs. 1 (range, 1-6), P=0.11 and 5.5 (range, 1.2-20.6) vs. 6.0 (range, 1.0-20.5) cm, P=0.24, respectively]. Tumor markers, including alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II), also did not differ between the groups (P=0.29 and P=0.36, respectively). The 5-year OS and CSS rates of the resection and palliative groups were 44.8% and 17.4% (P<0.001) and 47.7% and 18.6% (P<0.001), respectively. Multivariate analysis showed that palliative treatment intent was the most significant risk factor for OS and CSS [odds ratio (OR) =2.24; 95% confidence interval (CI): 1.66-3.02; P<0.001 and OR =2.29; 95% CI: 1.68-3.12; P<0.001, respectively].

Conclusions: Surgical resection could significantly improve OS and CSS in selected HCC with PVI patients who have preserved liver function and performance status.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
门静脉受侵肝细胞癌手术切除的临床意义:一项全国性队列研究。
背景:伴有门静脉侵犯(PVI)的肝细胞癌(HCC)被认为是预后不良的晚期阶段。尽管目前的指南建议对伴有门静脉侵犯的肝细胞癌进行全身治疗,但手术切除可为部分患者带来可接受的疗效。本研究旨在通过一项大规模的全国性登记,确定对伴有 PVI 的 HCC 患者进行手术切除的临床意义:这项回顾性、多中心、观察性队列研究分析了韩国原发性肝癌登记处的数据。共有16781名在2008年至2018年间新诊断为HCC的患者参与了这项研究。排除了Child-Turcotte-Pugh评分(≥7分)或表现状态(≥2分)较差的患者。其中,998 例接受过 PVI 治疗的 HCC 患者被纳入分析,并根据治疗意向分为两组:切除组 151 例(15.1%)和姑息组 847 例(84.9%),分别接受经动脉治疗和全身治疗。在对两组患者的肿瘤数量、大小和终末期肝病模型(MELD)评分进行匹配后,最终的研究分析队列包括切除组 151 例(26.6%)患者和姑息组 417 例(73.4%)患者。主要终点是总生存期(OS)和癌症特异性生存期(CSS):匹配后,切除组和姑息治疗组的 HCC 数量和最大尺寸没有差异[分别为 1(范围,1-5) vs. 1(范围,1-6),P=0.11 和 5.5(范围,1.2-20.6) vs. 6.0(范围,1.0-20.5)cm,P=0.24]。肿瘤标志物,包括甲胎蛋白(AFP)和维生素K缺失或拮抗剂-II(PIVKA-II)诱导的蛋白质,在两组之间也没有差异(分别为P=0.29和P=0.36)。切除组和姑息组的5年OS和CSS率分别为44.8%和17.4%(PConclusions:手术切除可明显改善肝功能和表现状况良好的HCC伴PVI患者的OS和CSS。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
10.00%
发文量
392
期刊介绍: Hepatobiliary Surgery and Nutrition (HBSN) is a bi-monthly, open-access, peer-reviewed journal (Print ISSN: 2304-3881; Online ISSN: 2304-389X) since December 2012. The journal focuses on hepatopancreatobiliary disease and nutrition, aiming to present new findings and deliver up-to-date, practical information on diagnosis, prevention, and clinical investigations. Areas of interest cover surgical techniques, clinical and basic research, transplantation, therapies, NASH, NAFLD, targeted drugs, gut microbiota, metabolism, cancer immunity, genomics, and nutrition and dietetics. HBSN serves as a valuable resource for professionals seeking insights into diverse aspects of hepatobiliary surgery and nutrition.
期刊最新文献
Risk stratification prior to major hepatectomy. Robotic liver resection for hepatocellular carcinoma: a new dawn? Should we resect distant metastases?-reconsidering radical resection of pancreatic cancer with liver metastases. Simulating the in vivo tumor microenvironment-advances in building a vascularized model of hepatocellular carcinoma through 3D bioprinting. Surgical resection of isolated pancreatic metastatic malignant melanoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1